JPRN-UMIN000008007已完成1 期
Phase I study on the combination therapy of IMF-001 and MIS416 for the treatment of patients with NY-ESO-1 expressing malignant solid tumor. - Phase I study on the combination therapy of IMF-001 and MIS416 for the treatment of patients with NY-ESO-1 expressing malignant solid tumor.
Mie University Graduate School of Medicine0 个研究点目标入组 12 人开始时间: 2012年5月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Past history of severe hypersensitivity. 2) Positive for HBs antigen, HCV antibody or HIV antibody. 3) Experience of autoimmune disease requiring treatment during 6 months prior to consent. 4) Active multiple primary malignancy. 5) Patient with disease requiring emergent radiotherapy. 6) Use of steroids (PSL >= 20mg / day) or immune-suppressive drugs. 7) Patients with severe complications. 8) History of other NY-ESO-1 related immunotherapy. 9) Pregnant or breastfeeding. 10) Patients who deny contraception during this study. 11) Any other cases that the attending doctor judges not appropriate to enroll to this study.
研究者
相似试验
招募中
不适用
A phase I study of conbination therapy with intratumorak administration of dendritic cells and radiation for far advanced esophageal cancerEsophageal cancerJPRN-UMIN000012218Chiba University6
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
已完成
1 期
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate CancerJPRN-UMIN000005246Mie University Graduate School of Medicine12
已完成
1 期
Exploratory trial of a combination therapy of mFolfirinox and immunotherapy against pancreatic cancer.Pancreatic cancerJPRN-UMIN000026009Department of Gastroenterology and Hepatology, School of Medicine, Kochi University1